Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
Radiopharm Theranostics announced the completion of patient enrollment in their U.S. Phase 2b imaging trial for RAD 101, a novel imaging agent targeting fatty acid synthase for detecting recurrent brain metastases. Interim data shows 90% concordance with MRI, with full data anticipated in June 2026. The company plans to advance RAD 101 into a Phase…